Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00048594
NCT00048594
Completed
Phase 3

A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Patients With Major Depressive Disorder

Merck Sharp & Dohme LLC0 sites800 target enrollmentJanuary 3, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMajor Depressive Disorder
DrugsaprepitantComparator: placebo (unspecified)

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Merck Sharp & Dohme LLC
Enrollment
800
Primary Endpoint
Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Detailed Description

The duration of treatment is 20 months.

Registry
clinicaltrials.gov
Start Date
January 3, 2002
End Date
December 22, 2003
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months

Time Frame: after 10 weeks of treatment and over 6-10 months

Secondary Outcomes

  • CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; an HAMA total score change from week 10 at Month 6.(Week 10 at Month 6)

Similar Trials

Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive Disorder
NCT00035048Merck Sharp & Dohme LLC540
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive Disorder
NCT00035282Merck Sharp & Dohme LLC450
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)Major Depressive Disorder
NCT00034983Merck Sharp & Dohme LLC900
Completed
Phase 2
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe PsoriasisModerate to Severe Chronic Plaque Psoriasis
NCT00601107Genzyme, a Sanofi Company111
Completed
Phase 3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive Disorder
NCT00035295Merck Sharp & Dohme LLC584